Teva Shares UZEDY® Transition Insights from Perseris®

Teva Pharmaceuticals unveiled new data at the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress in Milan that demonstrates the efficacy of switching patients to UZEDY, a long-acting injectable antipsychotic, four weeks after the last dose of the once-monthly Perseris® (RBP-7000). This switch offers a comparable pharmacokinetic (PK) profile according to relevant simulations, with matched doses identified.

In July 2024, the manufacturer of Perseris announced the cessation of its commercialization. Prior to this, Teva had already shared data in June 2024 outlining strategies for transitioning patients from the once-monthly intramuscular injection of Invega Sustenna® (paliperidone palmitate) to UZEDY. Richard Malamut, Chief Medical Officer of Medincell, expressed satisfaction with the support provided by their partner for healthcare providers in executing these switching strategies. UZEDY presents several advantages over other formulations of risperidone or paliperidone palmitate, including the elimination of loading doses or oral supplementation at initiation, flexible dosing intervals of one or two months, and subcutaneous administration via a ready-to-use prefilled syringe.

Additional results from the Advance study on the use of long-acting injectable antipsychotics were also presented by Teva at the ECNP Congress. Malamut highlighted that many concerns raised by patients with schizophrenia, their caregivers, and healthcare professionals about using long-acting injectable antipsychotics can be effectively addressed with UZEDY.

Medincell, the developer of UZEDY, is a biopharmaceutical company based in Montpellier, France. The company specializes in creating long-acting injectable drugs across various therapeutic areas. Medincell's innovative treatments are designed to ensure adherence to medical prescriptions, improve the effectiveness and accessibility of medications, and reduce environmental impact. These treatments incorporate Medincell's proprietary BEPO® technology, which controls drug delivery at therapeutic levels for several days, weeks, or months from a small, entirely bioresorbable subcutaneous or local injection.

The first treatment using BEPO® technology, aimed at treating schizophrenia, received FDA approval in April 2023 and is currently distributed in the United States under the name UZEDY by Teva. The BEPO® technology is licensed to Teva as SteadyTeq™. Medincell collaborates with leading pharmaceutical companies and foundations to enhance global health by providing new treatment options. The company employs over 140 individuals from more than 25 different nationalities, reflecting its global outlook and diverse expertise.

Through strategic partnerships and its innovative technology, Medincell aims to transform the landscape of long-acting injectable medications, offering improved treatment options and addressing the needs of patients and healthcare providers alike.